Indeed, many FAP-targeted drugs are now undergoing preclinical or clinical development for treatment of a variety of cancers 12, 13, including anti-FAP antibodies 14, 15, FAP-activated prodrugs 16-19, FAP-targeted radiotherapeutic agents 20-22, and FAP-directed cancer imaging agents 23-25. The gene discussed is FAP; the disease is cancer.